RxDoctor Payments Data

John Brandt, MD

Gastroenterology · Hot Springs, ARNPI 1558350900

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 279 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 45.3% of the total. Reporting peaked in 2021 at $957 and has fallen 59.9% since, to $383 in 2025. That places this record below the midpoint for gastroenterology clinicians in AR, where the typical reported total is $4,058.

$4,338in general payments, 2019–2025

Across 279 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$547
  • Takeda Pharmaceuticals U.S.A., Inc.$459
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$451
  • Intercept Pharmaceuticals, Inc.$129
  • Mauna Kea Technologies, Inc.$127
  • plus $660 from 14 others

What the payments were for

  • Food & beverage$4,28899%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,338 in reported general payments places this provider in the 50th percentile of 108 gastroenterology providers in Arkansas.

See all gastroenterology providers in Arkansas

Medicare billing

Part B allowed, 2024
$127,071
Medicare patients
574
Services billed
974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SimponiGolimumab13$93,686
LinzessLinaclotide41$28,259
ZenpepLipase/Protease/Amylase15$21,546
Omeprazole331$3,915
Balsalazide Disodium11$3,056
Budesonide DrBudesonide13$1,723
Pantoprazole Sodium137$1,510
Famotidine102$1,299
Sucralfate23$677
Esomeprazole Magnesium11$399
Metoclopramide Hcl13$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSimponi$106$93,68613 claims
AbbVieLinzess$1,965$28,25941 claims
Aimmune Therapeutics, Inc.Zenpep$120$21,54615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 108 gastroenterology providers in Arkansas.

Other gastroenterology in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →